Related references
Note: Only part of the references are listed.CD4 and CD8 lymphocyte subsets in cerebrospinal fluid and peripheral blood from patients with multiple sclerosis, meningitis and normal controls
M. Vrethem et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers
M. Khademi et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Expression of Chemokines and Their Receptors by Human Brain Endothelium: Implications for Multiple Sclerosis
Eve A. Subileau et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2009)
Therapeutic targeting of chemokine signaling in Multiple Sclerosis
Isabel Hamann et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2008)
Inflammatory cell migration into the central nervous system: A few new twists on an old tale
Shumei Man et al.
BRAIN PATHOLOGY (2007)
Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri (R)) in inflammatory diseases
Olaf Stueve et al.
CNS DRUG REVIEWS (2007)
Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies
Adam Szczucinski et al.
ACTA NEUROLOGICA SCANDINAVICA (2007)
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis
Olaf Stuve et al.
ARCHIVES OF NEUROLOGY (2006)
Immune surveillance in multiple sclerosis patients treated with natalizumab
O Stüve et al.
ANNALS OF NEUROLOGY (2006)
Natalizumab effects on immune cell responses in multiple sclerosis
M Niino et al.
ANNALS OF NEUROLOGY (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The expression and function of chemokines involved in CNS inflammation
EE Ubogu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2006)
Anti-α4 integrin therapy for multiple sclerosis -: Mechanisms and rationale
GPA Rice et al.
NEUROLOGY (2005)
Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis
DJ Hijnen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
IFN-γ-inducible chemokines enhance adaptive immunity and colitis
UP Singh et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2003)
Regulation of chemokine receptor expression in human microglia and astrocytes
G Flynn et al.
JOURNAL OF NEUROIMMUNOLOGY (2003)
A controlled trial of natalizumab for relapsing multiple sclerosis.
DH Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta 1a or glatiramer acetate compared with untreated patients
A Jansson et al.
MULTIPLE SCLEROSIS JOURNAL (2003)
Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis
T Fujisawa et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2002)
Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis
T Kakinuma et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2002)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies
D Franciotta et al.
JOURNAL OF NEUROIMMUNOLOGY (2001)
Expression of IFN-γ-inducible protein;: monocyte chemotactic proteins 1, 3, and 4;: and eotaxin in TH1-and TH2-mediated lung diseases
D Miotto et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2001)
Expression of the interferon-γ-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions
JE Simpson et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2000)
Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis
M Khademi et al.
JOURNAL OF NEUROIMMUNOLOGY (2000)
Share Paper
